Cellectis (NASDAQ:CLLS) Rating Lowered to “Hold” at StockNews.com

Cellectis (NASDAQ:CLLS) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

Cellectis Price Performance

CLLS stock traded up $0.04 during mid-day trading on Wednesday, reaching $1.31. 222,188 shares of the company’s stock were exchanged, compared to its average volume of 137,466. The company has a market cap of $72.82 million, a price-to-earnings ratio of -1.01 and a beta of 3.27. The stock’s 50 day moving average is $1.48 and its 200 day moving average is $1.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a 12-month low of $1.14 and a 12-month high of $3.38.

Cellectis (NASDAQ:CLLS) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.22). The firm had revenue of $33.22 million during the quarter, compared to analysts’ expectations of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. On average, research analysts expect that Cellectis will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

Several hedge funds and other institutional investors have recently made changes to their positions in the company. B Group Inc. purchased a new position in shares of Cellectis in the fourth quarter valued at approximately $5,547,000. Millennium Management LLC purchased a new position in Cellectis during the fourth quarter worth approximately $962,000. Finally, Wells Fargo & Company MN lifted its position in Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after buying an additional 12,500 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.